The company posted a consolidated net profit of Rs 554.6 crore for the January-March quarter, down 55% from the same period last year.<\/p>\n
Revenue from operations also declined 2.8% year-on-year to Rs 6,541.2 crore, while total expenses rose 8.5% to Rs 5,982.3 crore.<\/p>\n
The combination of weaker sales and higher expenses significantly impacted profitability during the quarter.<\/p>\n Despite weaker quarterly earnings, the company announced a final dividend of Rs 13 per equity share for FY26.<\/p>\n The dividend will be paid within 30 days of the annual general meeting after shareholder approval.<\/p>\n Cipla has fixed June 5, 2026, as the record date to determine eligible shareholders for the dividend payout.<\/p>\n The dividend announcement offered some support to long-term investor sentiment.<\/p>\n Read More<\/span> : Gold Import Duty Shock Pushes Jewellery Stocks 4% Lower as Bullion Prices Surge<\/a><\/p>\n Cipla\u2019s operating performance weakened considerably during the quarter.<\/p>\n EBITDA stood at Rs 997 crore compared to Rs 1,538 crore reported a year ago.<\/p>\n EBITDA margins also fell sharply to 15.2% from 22.8% in the corresponding quarter last year.<\/p>\n The company additionally reported an impairment charge of around Rs 42.02 crore linked to associates due to changing business conditions.<\/p>\n The biggest pressure on Cipla\u2019s earnings came from its North America business.<\/p>\n Revenue from the region declined 26% year-on-year to Rs 1,414 crore, impacting overall profitability.<\/p>\n However, other businesses delivered relatively stronger performance during the quarter.<\/p>\n India business revenue grew 15%, while Africa business increased 21% year-on-year.<\/p>\n The company said branded prescription drugs, trade generics and consumer health products continued to support domestic growth.<\/p>\n Investors reacted negatively after Cipla reported a sharp decline in profit and operating margins.<\/p>\n The weak performance in the North America market became the biggest concern for traders and analysts.<\/p>\n Rising expenses and shrinking EBITDA margins also increased fears of continued profitability pressure in coming quarters.<\/p>\n \u201cI am pleased to share that we continue to make progress across our focused markets,\u201d said Achin Gupta, MD and Global CEO of Cipla.<\/p>\n He added that the company achieved its highest-ever annual revenue despite near-term challenges in some markets.<\/p>\n For the full financial year FY26, Cipla reported revenue of Rs 28,163 crore, up 2% year-on-year.<\/p>\n However, annual net profit declined to Rs 3,879 crore from Rs 5,273 crore reported in FY25.<\/p>\n FY26 EBITDA margins also dropped to 21% from 25.9% in the previous year.<\/p>\n The numbers highlighted broader pressure on the company\u2019s profitability.<\/p>\n The company said its India business remained a key growth driver during the year.<\/p>\n Chronic therapies including respiratory, cardiac and anti-diabetes segments continued to deliver strong growth.<\/p>\n Cipla also highlighted progress in its differentiated portfolio and complex generics pipeline in the US market.<\/p>\n Management said future focus will remain on strengthening flagship brands and expanding pipeline investments.<\/p>\n The weak quarterly earnings may keep investors cautious in the near term.<\/p>\n The sharp decline in profit and margins could impact sentiment around pharma stocks with high US exposure.<\/p>\n However, analysts believe Cipla\u2019s strong India business and long-term product pipeline may continue to support growth prospects.<\/p>\n Investors are now expected to closely monitor future margin recovery and North America business performance.<\/p>\n The latest quarterly results highlighted rising operational challenges despite steady domestic growth.<\/p>\n The company\u2019s ability to improve margins and stabilise international business growth will remain a key focus area for the market.<\/p>\n Traders and long-term investors are likely to closely track upcoming quarterly performance before taking fresh positions in the stock.<\/p>\n","protected":false},"excerpt":{"rendered":" Cipla reports sharp fall in Q4 profit as costs rise Pharma major Cipla reported a steep decline in earnings for the fourth quarter of FY26, disappointing investors and putting pressure on sentiment around pharma stocks. The company posted a consolidated net profit of Rs 554.6 crore for the January-March quarter, down 55% from the same […]<\/p>\n","protected":false},"author":4,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[615],"tags":[1755,1758,1757,1756,1759,1762,1760,1761],"ppma_author":[1331],"class_list":{"0":"post-26017","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stock-market-news","8":"tag-cipla","9":"tag-cipla-dividend","10":"tag-cipla-fy26-results","11":"tag-cipla-q4-results","12":"tag-cipla-share-price","13":"tag-indian-pharma","14":"tag-pharma-stocks","15":"tag-pharmaceutical-sector"}," _eael_post_view_count":0,"authors":[{"term_id":1331,"user_id":4,"is_guest":0,"slug":"sourabh","display_name":"Sourabh Sharma","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/11\/Sourabh-Sharma.png","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/11\/Sourabh-Sharma.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/26017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=26017"}],"version-history":[{"count":1,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/26017\/revisions"}],"predecessor-version":[{"id":26021,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/26017\/revisions\/26021"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/26019"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=26017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=26017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=26017"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=26017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"Indian](\"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2026\/05\/Indian-Pharma-Stocks-Market.png\")
Cipla announces final dividend for shareholders<\/h2>\n
Why Cipla\u2019s Profit Fell So Sharply<\/h2>\n
\n\n
\n \nKey Reason<\/th>\n What Happened<\/th>\n Impact<\/th>\n<\/tr>\n<\/thead>\n \n Weak US Business<\/td>\n North America revenue dropped 26% YoY to \u20b91,414 crore<\/td>\n Biggest reason behind profit decline<\/td>\n<\/tr>\n \n Loss of High-Margin Products<\/td>\n gRevlimid contribution fell sharply after patent expiry; Lanreotide sales weakened<\/td>\n Hurt margins significantly<\/td>\n<\/tr>\n \n Revenue Decline<\/td>\n Q4 revenue fell 2.8% YoY to \u20b96,541 crore<\/td>\n Lower topline reduced profitability<\/td>\n<\/tr>\n \n Rising Expenses<\/td>\n Total expenses rose 8.5% YoY to \u20b95,982 crore<\/td>\n Increased operational pressure<\/td>\n<\/tr>\n \n EBITDA Crash<\/td>\n EBITDA dropped from \u20b91,538 crore to \u20b9997 crore<\/td>\n Operating profit weakened sharply<\/td>\n<\/tr>\n \n Margin Compression<\/td>\n EBITDA margin fell to 15.2% from 22.8%<\/td>\n Profitability deteriorated<\/td>\n<\/tr>\n \n Higher Marketing Costs<\/td>\n Spending increased for GLP launches and pipeline expansion<\/td>\n Added pressure on earnings<\/td>\n<\/tr>\n \n Freight & Supply Costs<\/td>\n Global freight costs rose amid geopolitical tensions<\/td>\n Increased operating expenses<\/td>\n<\/tr>\n \n Impairment Charge<\/td>\n Cipla booked \u20b942 crore impairment on associates<\/td>\n Additional hit to bottomline<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n EBITDA margins contract sharply in Q4 FY26<\/h2>\n
Major Indian Pharmaceutical Stocks: Price & Profit Growth (May 2026)<\/h2>\n
\n\n
\n \nCompany<\/th>\n Approx. Stock Price<\/th>\n Reported Profit Growth \/ Performance<\/th>\n<\/tr>\n<\/thead>\n \n Torrent Pharmaceuticals<\/a><\/td>\n \u20b94,180\u2013\u20b94,260<\/td>\n Strong growth momentum; semaglutide business gaining market share<\/td>\n<\/tr>\n \n Pfizer Ltd<\/a><\/td>\n \u20b95,400\u2013\u20b95,900<\/td>\n FY25 net profit growth reported around 39%<\/td>\n<\/tr>\n \n Emcure Pharmaceuticals<\/td>\n \u20b91,300\u2013\u20b91,500<\/td>\n Q4 FY25 consolidated profit reportedly up 64%<\/td>\n<\/tr>\n \n Aurobindo Pharma<\/a><\/td>\n \u20b91,150\u2013\u20b91,300<\/td>\n Quarterly profit crossed \u20b9910 crore in recent quarter<\/td>\n<\/tr>\n \n Mankind Pharma<\/a><\/td>\n \u20b92,200\u2013\u20b92,500<\/td>\n Strong domestic growth; stock showed sharp rally in recent months<\/td>\n<\/tr>\n \n Ajanta Pharma<\/a><\/td>\n \u20b92,700\u2013\u20b93,000<\/td>\n Q4 FY26 PAT growth reported around 18% YoY<\/td>\n<\/tr>\n \n Alkem Laboratories<\/a><\/td>\n \u20b95,200\u2013\u20b95,700<\/td>\n Stable India and US business growth<\/td>\n<\/tr>\n \n Cipla<\/a><\/td>\n \u20b91,420\u2013\u20b91,500<\/td>\n Q4 FY26 net profit plunged 55% YoY to \u20b9555 crore<\/td>\n<\/tr>\n \n Dr. Reddy\u2019s Laboratories<\/a><\/td>\n \u20b91,200\u2013\u20b91,300<\/td>\n Q4 FY26 net profit fell 86% YoY despite long-term growth outlook<\/td>\n<\/tr>\n \n Sun Pharma<\/a><\/td>\n \u20b91,800\u2013\u20b91,950<\/td>\n Strong specialty and domestic business growth continued<\/td>\n<\/tr>\n \n Divi\u2019s Laboratories<\/a><\/td>\n \u20b95,000\u2013\u20b95,700<\/td>\n Stable margins and export-led growth<\/td>\n<\/tr>\n \n Lupin<\/a><\/td>\n \u20b91,950\u2013\u20b92,150<\/td>\n Positive earnings outlook driven by US and India business<\/td>\n<\/tr>\n \n Zydus Lifesciences<\/a><\/td>\n \u20b91,000\u2013\u20b91,200<\/td>\n Moderate growth supported by chronic therapies<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n Weak North America business becomes a major concern<\/h2>\n
Here\u2019s what happened today and why traders reacted<\/h2>\n
Full-year earnings also reflect pressure on margins<\/h2>\n
Cipla continues to focus on India growth and pipeline expansion<\/h2>\n
What impact could Cipla\u2019s Q4 results have on investors?<\/h2>\n
Cipla investors may remain cautious in coming quarters<\/h2>\n